Cargando…

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL

Detalles Bibliográficos
Autores principales:	Tan, Yue, Cai, Haodong, Li, Chuo, Deng, Biping, Song, Weiliang, Ling, Zhuojun, Hu, Guang, Yang, Yongkun, Niu, Panpan, Meng, Guangrong, Cheng, Wei, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Yu, Xinjian, Feng, Xiaoming, Zhou, Jianfeng, Pan, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036232/ https://www.ncbi.nlm.nih.gov/pubmed/33839735 http://dx.doi.org/10.1038/s41408-021-00465-9

Ejemplares similares

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
por: Tan, Yue, et al.
Publicado: (2023)

Upregulation of CD22 by Chidamide promotes CAR T cells functionality
por: Yang, Xin, et al.
Publicado: (2021)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
por: Qiu, Yan, et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
por: Liu, Tingdang, et al.
Publicado: (2023)

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities
por: Rocco, Joseph M., et al.
Publicado: (2023)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023)

Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
por: Zheng, Sisi, et al.
Publicado: (2022)

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
por: Boissel, Nicolas, et al.
Publicado: (2023)

P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
por: Jain, N., et al.
Publicado: (2022)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
por: Spiegel, Jay Y., et al.
Publicado: (2021)

T-bet promotes potent antitumor activity of CD4(+) CAR T cells
por: Gacerez, Albert T, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p5q2cnvussg6igfl1gj6e7gr01